{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:42:36Z","timestamp":1783356156080,"version":"3.54.6"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ccm.2017.11.003","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:08:35Z","timestamp":1513123715000},"page":"195-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intracavitary Therapeutics for Pleural Malignancies"],"prefix":"10.1016","volume":"39","author":[{"given":"Vivek","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav","family":"Mangalick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Sterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21037\/jtd.2017.04.65","article-title":"Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS","volume":"9","author":"Hu","year":"2017","journal-title":"J\u00a0Thorac Dis"},{"issue":"8","key":"10.1016\/j.ccm.2017.11.003_bib2","first-page":"4587","article-title":"Better clinical efficiency of TILs for malignant pleural effusion and ascites than cisplatin through intrapleural and intraperitoneal infusion","volume":"37","author":"Chu","year":"2017","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ccm.2017.11.003_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bjc.6603319","article-title":"Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial","volume":"95","author":"Seto","year":"2006","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/02656736.2017.1301576","article-title":"Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI)","volume":"33","author":"Goere","year":"2017","journal-title":"Int J Hyperthermia"},{"issue":"24 Suppl","key":"10.1016\/j.ccm.2017.11.003_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fon.15.286","article-title":"Pleurectomy\/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience","volume":"11","author":"Migliore","year":"2015","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib6","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.rmed.2013.01.010","article-title":"Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies","volume":"107","author":"Isik","year":"2013","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.ccm.2017.11.003_bib7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11748-015-0535-x","article-title":"Interim results of pleurectomy\/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy","volume":"63","author":"Ishibashi","year":"2015","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"7","key":"10.1016\/j.ccm.2017.11.003_bib8","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.21037\/jtd.2016.06.04","article-title":"Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination","volume":"8","author":"Yi","year":"2016","journal-title":"J\u00a0Thorac Dis"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00432-013-1526-x","article-title":"Intrapleural hyperthermic perfusion using distilled water at 48 degrees C for malignant pleural effusion","volume":"139","author":"Ba","year":"2013","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib10","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.18632\/oncotarget.6491","article-title":"EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtcvs.2012.12.037","article-title":"Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection","volume":"145","author":"Sugarbaker","year":"2013","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"1\u20132","key":"10.1016\/j.ccm.2017.11.003_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2015.02.048","article-title":"Biodegradable drug-eluting pellets provide steady and sustainable cisplatin release in the intrapleural cavity: in\u00a0vivo and in\u00a0vitro studies","volume":"484","author":"Chao","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ccm.2017.11.003_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-210044","article-title":"Intrapleural cisplatin for management of malignant pleural effusion in a patient with plasma cell leucaemia","volume":"2015","author":"Agarwal","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib14","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.7314\/APJCP.2013.14.4.2611","article-title":"Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites","volume":"14","author":"Huang","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/COC.0b013e318256f5ba","article-title":"An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma","volume":"36","author":"Ellithy","year":"2013","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ccm.2017.11.003_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s00595-012-0281-y","article-title":"Intrapleural chemotherapy improves the survival of non-small cell lung cancer patients with positive pleural lavage cytology","volume":"43","author":"Baba","year":"2013","journal-title":"Surg Today"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/08977199409015049","article-title":"Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma","volume":"11","author":"Fitzpatrick","year":"1994","journal-title":"Growth Factors"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1165\/ajrcmb.12.5.7742009","article-title":"The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma","volume":"12","author":"Fitzpatrick","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib19","first-page":"258","article-title":"The alveolar macrophage: immune derangement and asbestos-related malignancy","volume":"8","author":"Kagan","year":"1981","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00918702","article-title":"High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma","volume":"6","author":"Lew","year":"1986","journal-title":"J\u00a0Clin Immunol"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib21","doi-asserted-by":"crossref","first-page":"djx097","DOI":"10.1093\/jnci\/djx097","article-title":"Local immunotherapy of cancer: innovative approaches to harnessing tumor-specific immune responses","volume":"109","author":"Murthy","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ccm.2017.11.003_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.21037\/atm.2017.03.81","article-title":"Novel immunotherapy clinical trials in malignant pleural mesothelioma","volume":"5","author":"Tano","year":"2017","journal-title":"Ann Transl Med"},{"issue":"15","key":"10.1016\/j.ccm.2017.11.003_bib23","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib24","first-page":"840","article-title":"Human malignant mesothelioma cell growth: activation of janus kinase 2 and signal transducer and activator of transcription 1alpha for inhibition by interferon-gamma","volume":"58","author":"Buard","year":"1998","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ccm.2017.11.003_bib25","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/1097-0142(19910415)67:8<2033::AID-CNCR2820670804>3.0.CO;2-8","article-title":"Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma","volume":"67","author":"Boutin","year":"1991","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ccm.2017.11.003_bib26","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N","article-title":"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma","volume":"74","author":"Boutin","year":"1994","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ccm.2017.11.003_bib27","first-page":"4419","article-title":"Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment","volume":"54","author":"Monti","year":"1994","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ccm.2017.11.003_bib28","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1378\/chest.121.6.1921","article-title":"Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study","volume":"121","author":"Monnet","year":"2002","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2017.11.003_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002620050407","article-title":"Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer","volume":"45","author":"Yanagawa","year":"1997","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.12845","article-title":"Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer","volume":"186","author":"Hu","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"Goey","year":"1995","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ccm.2017.11.003_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2169\/internalmedicine.45.1538","article-title":"Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients","volume":"45","author":"Shimizu","year":"2006","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1440-1843.2006.00790.x","article-title":"Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer","volume":"11","author":"Ishida","year":"2006","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2007.07.009","article-title":"Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515","volume":"58","author":"Yoshida","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ccm.2017.11.003_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"issue":"14","key":"10.1016\/j.ccm.2017.11.003_bib36","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-07-0224","article-title":"Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand","volume":"67","author":"Liu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ccm.2017.11.003_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-017-2025-8","article-title":"Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer","author":"Hamid","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib38","doi-asserted-by":"crossref","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A\u00a0phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib40","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A\u00a0trial of intrapleural adenoviral-mediated Interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib41","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/j.jtho.2016.11.305","article-title":"OA13.07 intrapleural modified vaccine strain measles virus therapy for patients with malignant pleural mesothelioma","volume":"12","author":"Peikert","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.ccm.2017.11.003_bib42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.cgt.7700935","article-title":"Gene therapy for malignant mesothelioma: beyond the infant years","volume":"13","author":"van der Most","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"10.1016\/j.ccm.2017.11.003_bib43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1089\/hum.1998.9.7-1083","article-title":"Adenovirus-mediated herpes simplex virus thymidine kinase\/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma","volume":"9","author":"Sterman","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib44","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/sj.cgt.7700269","article-title":"A\u00a0pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma","volume":"7","author":"Sterman","year":"2000","journal-title":"Cancer Gene Ther"},{"issue":"15 Pt 1","key":"10.1016\/j.ccm.2017.11.003_bib45","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A\u00a0phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ccm.2017.11.003_bib46","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2001.19.14.3422","article-title":"Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial","volume":"19","author":"Hortobagyi","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ccm.2017.11.003_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0003-4975(00)01557-5","article-title":"Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma","volume":"70","author":"Harrison","year":"2000","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.ccm.2017.11.003_bib48","first-page":"1273","article-title":"Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin","volume":"36","author":"Dong","year":"2008","journal-title":"J\u00a0Int Med Res"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib49","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/cgt.2011.60","article-title":"Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study","volume":"18","author":"Schwarzenberger","year":"2011","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib50","first-page":"1324","article-title":"Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer","volume":"28","author":"Zhao","year":"2009","journal-title":"Ai Zheng"},{"issue":"suppl_5","key":"10.1016\/j.ccm.2017.11.003_bib51","first-page":"mdx367.001","article-title":"366PDOncolytic herpesvirus therapy for mesothelioma: a phase I\/IIa trial of intrapleural administration of HSV1716 (NCT01721018)","volume":"28","author":"Danson","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ccm.2017.11.003_bib52","first-page":"591","article-title":"Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells","volume":"5","author":"Giuliano","year":"2000","journal-title":"Int J Mol Med"},{"issue":"11","key":"10.1016\/j.ccm.2017.11.003_bib53","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/sj.cgt.7700241","article-title":"Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus","volume":"7","author":"Frizelle","year":"2000","journal-title":"Cancer Gene Ther"},{"issue":"16","key":"10.1016\/j.ccm.2017.11.003_bib54","first-page":"5959","article-title":"p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53","volume":"61","author":"Yang","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mtc.2001.111419","article-title":"Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines","volume":"121","author":"Pataer","year":"2001","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"24","key":"10.1016\/j.ccm.2017.11.003_bib56","first-page":"6068","article-title":"Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells","volume":"59","author":"Waheed","year":"1999","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib57","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1089\/10430340260185102","article-title":"Gene transfer to the pleural mesothelium as a strategy to deliver proteins to the lung parenchyma","volume":"13","author":"Mae","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib58","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.athoracsur.2004.03.021","article-title":"Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma","volume":"78","author":"Merritt","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"10.1016\/j.ccm.2017.11.003_bib59","first-page":"2955","article-title":"Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models","volume":"60","author":"Lanuti","year":"2000","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.ccm.2017.11.003_bib60","first-page":"2641","article-title":"The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study","volume":"9","author":"Schwarzenberger","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib61","first-page":"168","article-title":"Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana","volume":"150","author":"Schwarzenberger","year":"1998","journal-title":"J\u00a0La State Med Soc"},{"issue":"9","key":"10.1016\/j.ccm.2017.11.003_bib62","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1089\/hum.1997.8.9-1105","article-title":"Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene","volume":"8","author":"Aoki","year":"1997","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.ccm.2017.11.003_bib63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/sj.cgt.7700080","article-title":"Suicidal gene therapy for pleural metastasis of lung cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene","volume":"6","author":"Nagamachi","year":"1999","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.ccm.2017.11.003_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2004.03.013","article-title":"Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy","volume":"46","author":"Berlinghoff","year":"2004","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00000658-199507000-00013","article-title":"Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene","volume":"222","author":"Smythe","year":"1995","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1165\/ajrcmb.13.1.7598939","article-title":"Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in\u00a0vivo models of human malignant mesothelioma and lung cancer","volume":"13","author":"Hwang","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.ccm.2017.11.003_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/hum.1996.7.2-141","article-title":"Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene","volume":"7","author":"Elshami","year":"1996","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib68","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.gt.3300385","article-title":"Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene","volume":"4","author":"Esandi","year":"1997","journal-title":"Gene Ther"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/mthe.2001.0463","article-title":"Antitumor activity of cationic lipid complexed with immunostimulatory DNA","volume":"4","author":"Rudginsky","year":"2001","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.ccm.2017.11.003_bib70","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/icb.1997.55","article-title":"The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer","volume":"75","author":"Leong","year":"1997","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib71","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1165\/ajrcmb.21.3.3575","article-title":"Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12","volume":"21","author":"Caminschi","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"10.1016\/j.ccm.2017.11.003_bib72","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.cgt.7700347","article-title":"The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor","volume":"8","author":"Mukherjee","year":"2001","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ijc.20574","article-title":"Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte\/macrophage colony stimulating factor in mesothelioma","volume":"113","author":"Triozzi","year":"2005","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.ccm.2017.11.003_bib74","first-page":"3298","article-title":"Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma","volume":"8","author":"Gattacceca","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ccm.2017.11.003_bib75","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.cgt.7700594","article-title":"Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma","volume":"10","author":"Cordier Kellerman","year":"2003","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"10.1016\/j.ccm.2017.11.003_bib76","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/BF03402093","article-title":"Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL","volume":"8","author":"Cao","year":"2002","journal-title":"Mol Med"},{"issue":"3 Pt 1","key":"10.1016\/j.ccm.2017.11.003_bib77","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1165\/rcmb.2002-0226OC","article-title":"Efficacy of CD40 ligand gene therapy in malignant mesothelioma","volume":"29","author":"Friedlander","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"16","key":"10.1016\/j.ccm.2017.11.003_bib78","first-page":"6201","article-title":"Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity","volume":"61","author":"Odaka","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ccm.2017.11.003_bib79","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/mthe.2002.0656","article-title":"Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy","volume":"6","author":"Odaka","year":"2002","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib80","first-page":"237","article-title":"Incorporating the\u00a0survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in\u00a0vitro and in\u00a0vivo","volume":"27","author":"Zhu","year":"2005","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.ccm.2017.11.003_bib81","first-page":"466","article-title":"Use of a \u201creplication-restricted\u201d herpes virus to treat experimental human malignant mesothelioma","volume":"57","author":"Kucharczuk","year":"1997","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jgm.877","article-title":"Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses","volume":"8","author":"Adusumilli","year":"2006","journal-title":"J\u00a0Gene Med"},{"issue":"1","key":"10.1016\/j.ccm.2017.11.003_bib83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.cgt.7700860","article-title":"Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer","volume":"13","author":"Stiles","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib84","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.cgt.7700133","article-title":"Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation","volume":"7","author":"Mukherjee","year":"2000","journal-title":"Cancer Gene Ther"},{"issue":"14","key":"10.1016\/j.ccm.2017.11.003_bib85","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1089\/hum.1998.9.14-2121","article-title":"Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma","volume":"9","author":"Molnar-Kimber","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"20","key":"10.1016\/j.ccm.2017.11.003_bib86","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","article-title":"Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy","volume":"11","author":"Sterman","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ccm.2017.11.003_bib87","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/cgt.2012.36","article-title":"Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review","volume":"19","author":"Zarogoulidis","year":"2012","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.ccm.2017.11.003_bib88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ymthe.2004.10.015","article-title":"Fighting cancer with vaccinia virus: teaching new tricks to an old dog","volume":"11","author":"Shen","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.ccm.2017.11.003_bib89","article-title":"A\u00a0randomized phase II single center study of gene transfer-based non-specific immunotherapy of malignant mesothelioma (MM) by intratumoral injections of an interleukin-2 producing vero cells","volume":"22","author":"Pitako","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.ccm.2017.11.003_bib90","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ncponc0658","article-title":"Interferon beta adenoviral gene therapy in a patient with ovarian cancer","volume":"3","author":"Sterman","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"22","key":"10.1016\/j.ccm.2017.11.003_bib91","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediated regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ccm.2017.11.003_bib92","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2016-0008","article-title":"A\u00a0regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial","volume":"8","author":"Mayor","year":"2016","journal-title":"Immunotherapy"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523117301107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523117301107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:53:34Z","timestamp":1759452814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523117301107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0272523117301107"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2017.11.003","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracavitary Therapeutics for Pleural Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}